Free Trial

This company has been marked as potentially delisted and may not be actively trading.

NASDAQ:DMTK

DermTech (DMTK) Stock Price, News & Analysis

DermTech logo

About DermTech Stock (NASDAQ:DMTK)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.05
$0.42
52-Week Range
N/A
Volume
3.66 million shs
Average Volume
1.07 million shs
Market Capitalization
$3.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

DermTech, Inc., a molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States. The company provides DermTech Melanoma Test (DMT), an innovative non-invasive way to enhance melanoma detection for developing product for non-melanoma skin cancers. It also offers DermTech Smart Sticker, which provides a non-invasively way to collect skin sample including standard care by using scalpel to biopsy suspicious lesions. In addition, it provides research services and technology platform on a contract basis to pharmaceutical companies which use the technology for clinical trials. Further, the company develops gene expression assays for the psoriasis, atopic dermatitis, and aging of the skin to pharmaceutical companies to develop drug products in dermatology; and develop custom gene assays to support the pharmaceutical partners. It sells its products through pathology and oncology practitioners. DermTech, Inc. is headquartered in San Diego, California.

Receive DMTK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for DermTech and its competitors with MarketBeat's FREE daily newsletter.

DMTK Stock News Headlines

North American Morning Briefing: TSMC Earnings -2-
DermTech, Inc. (DMTKQ)
What President Trump’s Executive Order 14154 means for your money
Nearly $3 trillion disappeared from the stock market on Thursday morning. According to Whitney Tilson - a former hedge fund manager who predicted the dotcom crash, the housing crisis, and the 2022 tech stock bloodbath - a little-known executive order from the President's first day in office could spark a paradigm-shift that will likely catch millions of Americans off guard.
Victory RS Small Cap Growth A
Why Is DermTech (DMTK) Stock Down 26% Today?
DermTech Files for Voluntary Chapter 11 Protection
See More Headlines

DMTK Stock Analysis - Frequently Asked Questions

DermTech, Inc. (NASDAQ:DMTK) released its quarterly earnings data on Tuesday, November, 9th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by $0.03. The company earned $3.03 million during the quarter, compared to analyst estimates of $3.40 million. DermTech had a negative net margin of 572.19% and a negative trailing twelve-month return on equity of 138.79%.

Based on aggregate information from My MarketBeat watchlists, some other companies that DermTech investors own include CrowdStrike (CRWD), NVIDIA (NVDA), Digital Turbine (APPS), Datadog (DDOG) and Cloudflare (NET).

Company Calendar

Last Earnings
11/09/2021
Today
5/02/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical laboratories
Sub-Industry
Healthcare
Current Symbol
NASDAQ:DMTK
Fax
N/A
Employees
260
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-100,890,000.00
Net Margins
-572.19%
Pretax Margin
-572.19%

Debt

Sales & Book Value

Annual Sales
$15.66 million
Price / Cash Flow
N/A
Book Value
$1.67 per share
Price / Book
N/A

Miscellaneous

Free Float
33,180,000
Market Cap
$3.29 million
Optionable
Optionable
Beta
2.48
7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

This page (NASDAQ:DMTK) was last updated on 5/3/2025 by MarketBeat.com Staff
From Our Partners